Faculty
Todd Fehniger.jpg

Todd A. Fehniger, MD, PhD

Associate Professor
Department of Medicine
Oncology Division
Stem Cell Biology
Bone Marrow Transplantation & Leukemia

Clinical Interests

  • Lymphoma
  • Leukemia
  • Immunotherapy
  • Hematopoietic cell transplantation

Research Interests

  • Innate immunity
  • Natural killer cell biology
  • Micro RNAs
  • Cytokines
  • Natural killer cell based therapeutics

Contact

  • 314-747-1547 (lab)
  • 314-747-1385 (lab office)
  • 314-362-9333 (fax)
  • 6th Floor Southwest Tower, Room 638 (office)
  • 6th Floor Southwest Tower, Room 634 (lab)
  • Division of Oncology
    Section of Stem Cell Biology
    Campus Box 8007
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Fehniger Laboratory

Peer-reviewed Articles

  • CD70 turns on NK cells to attack lymphoma
    Fehniger TA
    Blood 2017 Jul 20;130(3):238-239
  • A phase I/II trial of panobinostat in combination with lenalidomide in patients with relapsed or refractory Hodgkin lymphoma
    Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, Bartlett NL, Blum KA
    Clin Lymphoma Myeloma Leuk 2017 Jun;17(6):347-353
  • Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study
    Goyal S, Oak E, Luo J, Cashen AF, Carson K, Fehniger T, DiPersio J, Bartlett NL, Wagner-Johnston ND
    Leuk Lymphoma 2017 Jun 9:1-6; [Epub ahead of print]
  • Transcriptional and post-transcriptional regulation of NK cell development and function
    Leong JW, Wagner JA, Ireland AR, Fehniger TA
    Clin Immunol 2017 Apr;177:60-69
  • Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation
    Huselton E, Slade M, DiPersio JF, Westervelt P, Vij R, Uy GL, Fehniger TA, Abboud CN, Gao F, Schroeder MA, Romee R
    Bone Marrow Transplant 2017 May;52(5):769-771
  • T cell-replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia
    How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2017 Apr;23(4):648-653
  • Longitudinal body composition changes in diffuse large B-cell lymphoma survivors: a retrospective cohort study of United States veterans
    Xiao DY, Luo S, O'Brian K, Sanfilippo KM, Ganti A, Riedell P, Lynch RC, Liu W, Kahl BS, Cashen AF, Fehniger TA, Carson KR
    J Natl Cancer Inst 2016 Jul 5;108(11):djw145
  • Cytokine-induced memory-like differentiation enhances unlicensed natural killer cell antileukemia and FcgammaRIIIa-triggered responses
    Wagner JA, Berrien-Elliott MM, Rosario M, Leong JW, Jewell BA, Schappe T, Abdel-Latif S, Fehniger TA
    Biol Blood Marrow Transplant 2017 Mar;23(3):398-404
  • Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma
    Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA
    Blood 2017 Jan 26;129(4):473-483
  • Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis
    Cantoni C, Cignarella F, Ghezzi L, Mikesell B, Bollman B, Berrien-Elliott MM, Ireland AR, Fehniger TA, Wu GF, Piccio L
    Acta Neuropathol 2017 Jan;133(1):61-77
  • TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ
    N Engl J Med 2016 Nov 24;375(21):2023-2036
  • Harnessing NK cell memory for cancer immunotherapy
    Fehniger TA, Cooper MA
    Trends Immunol 2016 Dec;37(12):877-888
  • Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide
    Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R
    Haematologica 2016 Nov;101(11):e465-e468
  • Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
    Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, Neal CC, Yu L, Oh ST, Lee YS, Mulder A, Claas F, Cooper MA, Fehniger TA
    Sci Transl Med 2016 Sep 21;8(357):357ra123
  • Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated
    Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R
    Biol Blood Marrow Transplant 2016 Oct;22(10):1851-60
  • Comparison of outcomes after peripheral blood haploidentical versus matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single-center review
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2016 Sep;22(9):1696-701
  • HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Pusic I, Cashen AF, Fehniger TA, Romee R
    Bone Marrow Transplant 2016 Sep;51(9):1275-8
  • The IL-15-based ALT-803 complex enhances FcgammaRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas
    Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell BA, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms DR, Cashen AF, Bartlett NL, Wong HC, Fehniger TA
    Clin Cancer Res 2016 Feb 1;22(3):596-608
  • Improving natural killer cell cancer immunotherapy
    Berrien-Elliott MM, Romee R, Fehniger TA
    Curr Opin Organ Transplant 2015 Dec;20(6):671-680
  • MicroRNA-15/16 antagonizes Myb to control NK cell maturation
    Sullivan RP, Leong JW, Schneider SE, Ireland AR, Berrien-Elliott MM, Singh A, Schappe T, Jewell BA, Sexl V, Fehniger TA
    J Immunol 2015 Sep 15;195(6):2806-17
  • Human cytokine-induced memory-like natural killer cells
    Berrien-Elliott MM, Wagner JA, Fehniger TA
    J Innate Immun 2015;7(6):563-571
  • Hematologic recovery after pretransplant chemotherapy does not influence survival after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients
    Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R
    Biol Blood Marrow Transplant 2015 Aug;21(8):1425-30
  • PTEN regulates natural killer cell trafficking in vivo
    Leong JW, Schneider SE, Sullivan RP, Parikh BA, Anthony BA, Singh A, Jewell BA, Schappe T, Wagner JA, Link DC, Yokoyama WM, Fehniger TA
    Proc Natl Acad Sci U S A 2015 Feb 17;112(7):E700-9
  • Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma
    Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O'Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, Colditz GA
    J Geriatr Oncol 2015 May;6(3):211-8
  • MicroRNA management of NK-cell developmental and functional programs
    Leong JW, Sullivan RP, Fehniger TA
    Eur J Immunol 2014 Oct;44(10):2862-8
  • Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer
    Romee R, Leong JW, Fehniger TA
    Scientifica (Cairo) 2014;2014:205796
  • Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes
    Bhamidipati PK, DiPersio JF, Stockerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R
    Bone Marrow Transplant 2014 Aug;49(8):1124-6
  • Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells
    Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, Fehniger TA
    Biol Blood Marrow Transplant 2014 Apr;20(4):463-73
  • Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen
    Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R
    Biol Blood Marrow Transplant 2014 Jan;20(1):46-52
  • MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways
    Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, Sexl V, Matkovich SJ, Dorn GW 2nd, French AR, Fehniger TA
    J Immunol 2013 Dec 15;191(12):5904-13
  • MicroRNA regulation of natural killer cells
    Sullivan RP, Leong JW, Fehniger TA
    Front Immunol 2013;4:44
  • Lenalidomide-mediated enhanced translation of C/EBPalpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia
    Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrozek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G
    Blood 2013 Jan 3;121(1):159-69
  • Natural killer cell regulation by microRNAs in health and disease
    Leong JW, Sullivan RP, Fehniger TA
    J Biomed Biotechnol 2012;2012:632329
  • Cytokine activation induces human memory-like NK cells
    Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, Cooper MA, Fehniger TA
    Blood 2012 Dec 6;120(24):4751-60
  • MicroRNA-deficient NK cells exhibit decreased survival but enhanced function
    Sullivan RP, Leong JW, Schneider SE, Keppel CR, Germino E, French AR, Fehniger TA
    J Immunol 2012 Apr 1;188(7):3019-30
  • T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome
    Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J
    Biol Blood Marrow Transplant 2012 Jun;18(6):937-43
  • A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
    Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL
    Blood 2011 Nov 10;118(19):5119-25
  • Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation
    Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, DiPersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA
    Biol Blood Marrow Transplant 2011 Nov;17(11):1646-52
  • A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
    Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Westervelt P, DiPersio JF, Vij R
    Blood 2011 Feb 10;117(6):1828-33
  • Next-generation sequencing identifies the natural killer cell microRNA transcriptome
    Fehniger TA, Wylie T, Germino E, Leong JW, Magrini VJ, Koul S, Keppel CR, Schneider SE, Koboldt DC, Sullivan RP, Heinz ME, Crosby SD, Nagarajan R, Ramsingh G, Link DC, Ley TJ, Mardis ER
    Genome Res 2010 Nov;20(11):1590-604
  • Complete characterization of the microRNAome in a patient with acute myeloid leukemia
    Ramsingh G, Koboldt DC, Trissal M, Chiappinelli KB, Wylie T, Koul S, Chang LW, Nagarajan R, Fehniger TA, Goodfellow P, Magrini V, Wilson RK, Ding L, Ley TJ, Mardis ER, Link DC
    Blood 2010 Dec 9;116(24):5316-5326
  • Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice
    Martin MG, Welch JS, Uy GL, Fehniger TA, Kulkarni S, Duncavage EJ, Walter MJ
    Leukemia 2010 Sep;24(9):1662-4
  • Latent herpesvirus infection arms NK cells
    White DW, Keppel CR, Schneider SE, Reese TA, Coder J, Payton JE, Ley TJ, Virgin HW, Fehniger TA
    Blood 2010 Jun 3;115(22):4377-83
  • Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease
    Cai SF, Cao X, Hassan A, Fehniger TA, Ley TJ
    Blood 2010 Mar 4;115(9):1669-77
  • Differential expression of granzyme B and C in murine cytotoxic lymphocytes
    Cai SF, Fehniger TA, Cao X, Mayer JC, Brune JD, French AR, Ley TJ
    J Immunol 2009 May 15;182(10):6287-97
  • Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13
    Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W
    Blood 2009 Jan 29;113(5):1002-5
  • Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance
    Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ
    Immunity 2007 Oct;27(4):635-46
  • Chronic lymphocytosis of functionally immature natural killer cells
    French AR, Kim S, Fehniger TA, Pratt JR, Yang L, Song YJ, Caligiuri MA, Yokoyama WM
    J Allergy Clin Immunol 2007 Oct;120(4):924-31
  • Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs
    Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, Ley TJ
    Immunity 2007 Jun;26(6):798-811
  • Hop cleavage and function in granzyme B-induced apoptosis
    Bredemeyer AJ, Carrigan PE, Fehniger TA, Smith DF, Ley TJ
    J Biol Chem 2006 Dec 1;281(48):37130-41
  • CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity
    Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA
    Blood 2003 Apr 15;101(8):3052-7
  • Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420
    Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger TA, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA
    Clin Cancer Res 2002 Sep;8(9):2812-9
  • In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells
    Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA
    Blood 2002 Nov 15;100(10):3633-8
  • Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
    Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA
    Blood 2002 Sep 15;100(6):1935-47
  • Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system
    Comella K, Nakamura M, Melnik K, Chosy J, Zborowski M, Cooper MA, Fehniger TA, Caligiuri MA, Chalmers JJ
    Cytometry 2001 Dec 1;45(4):285-93
  • The biology of human natural killer-cell subsets. [Review]
    Cooper MA, Fehniger TA, Caligiuri MA
    Trends Immunol 2001 Nov;22(11):633-40
  • Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset
    Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA
    Blood 2001 May 15;97(10):3146-51
  • Interleukin-1beta costimulates interferon-gamma production by human natural killer cells
    Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, Caligiuri MA
    Eur J Immunol 2001 Mar;31(3):792-801
  • Interleukin 15: biology and relevance to human disease. [Review]
    Fehniger TA, Caligiuri MA
    Blood 2001 Jan 1;97(1):14-32
  • Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells
    Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA
    J Exp Med 2001 Jan 15;193(2):219-31
  • Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy
    Fehniger TA, Bluman EM, Porter MM, Mrozek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA
    J Clin Invest 2000 Jul;106(1):117-24
  • Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo
    Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA
    J Immunol 2000 Feb 15;164(4):1643-7
  • Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response
    Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA
    J Immunol 1999 Apr 15;162(8):4511-20
  • Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15
    Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE, Caligiuri MA
    Blood 1998 Nov 15;92(10):3647-57
  • Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection
    Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O'Brien WA, Caligiuri MA
    J Immunol 1998 Dec 1;161(11):6433-8
  • Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing
    Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA
    Cancer Immunol Immunother 1998 Aug;46(6):318-26
  • Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets
    Frey M, Packianathan NB, Fehniger TA, Ross ME, Wang WC, Stewart CC, Caligiuri MA, Evans SS
    J Immunol 1998 Jul 1;161(1):400-8
  • Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies
    Khatri VP, Fehniger TA, Baiocchi RA, Yu F, Shah MH, Schiller DS, Gould M, Gazzinelli RT, Bernstein ZP, Caligiuri MA
    J Clin Invest 1998 Mar 15;101(6):1373-8
  • Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo
    Fehniger TA, Carson WE, Mrozek E, Caligiuri MA
    Blood 1997 Nov 1;90(9):3647-53
  • CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand
    Carson WE, Fehniger TA, Caligiuri MA
    Eur J Immunol 1997 Feb;27(2):354-60
  • A potential role for interleukin-15 in the regulation of human natural killer cell survival
    Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA
    J Clin Invest 1997 Mar 1;99(5):937-43